Business Wire

NY-AQARA

Share
Aqara Releases Hub M3 to Global Markets

Aqara, a leading provider of smart home products, announced the global availability of its next-generation Matter hub, the Hub M3. Designed with a focus on edge computing, the M3 prioritizes privacy and local automation capabilities that can operate independently of internet connection or even the hub itself1. Thanks to the versatile connectivity built-in, it seamlessly integrates Aqara accessories, infrared-compatible gadgets and a number of third-party Matter devices, making it a central point for smart home automation while ensuring privacy and easy setup.

“Aqara is committed to creating the ultimate smart home experience that continuously adapts to users’ evolving needs,” said Cathy You, Aqara Senior Vice President of Global Business and Strategy. “The Hub M3's edge computing capabilities will provide users with an added layer of stability and safety, while its Matter compatibility will significantly enhance interoperability and choice for users."

Debuted at CES in January, the M3 stands out as an Edge Hub by enabling not only data privacy through end-to-end encrypted, local storage but also advanced, local automation capabilities. For Aqara users who already own an Aqara Zigbee hub, deploying a Hub M3 further strengthens the robustness of their smart home networks. Moreover, it enables more local automations between Aqara devices. Once added to the network, the M3 takes a lead over other Aqara Zigbee hubs and Wi-Fi devices, and allows automation between these devices to execute on the Edge instead of over the cloud, ensures continued functionality during internet or cloud service disruptions2. The Hub M3 also allows select Aqara Zigbee devices with Repeater functionality to act as a proxy hub and execute automations in the absence of M3. Upcoming Aqara Thread devices with Mesh Extender functionality are expected to support device binding via the M3.

As the latest evolution in Aqara’s lineup of smart home control centers, the M3 supports multiple protocols including Thread, Zigbee, Wi-Fi, Bluetooth and infrared (IR), making it a comprehensive hub for smart home management. It connects and manages the lineup of classic Aqara Zigbee devices, serving as a Matter bridge3. Thanks to the 360° IR blaster, the new hub optimizes control of IR-enabled devices by syncing their status directly with Aqara Home whenever an IR remote is utilized. Moreover, the M3 integrates the latest Aqara Thread devices as well as select Matter-compatible devices from third-party brands to Aqara Home4. This means that users can connect and manage devices from different brands and ecosystems within the Aqara Home app to ensure maximum flexibility and compatibility.

Other enhancements of the Hub M3 include:

  • Matter bridge for infrared AC units: It can integrate an infrared-compatible air conditioning unit or air-to-air heat pump to Matter, allowing for AC control and automation via Matter-enabled platforms5.
  • Seamless group migration: Users can easily migrate bridged device from older Aqara hubs to the M32, ensuring continuity of Aqara Home settings and automations without the need to reconfigure each device.
  • Enhanced internet connectivity: The M3 features dual-band Wi-Fi (2.4GHz/5GHz) with WPA3 security as well as a PoE-enabled port, offering enhanced stability and flexibility.
  • Powerful speaker: The 95dB speaker built-in can be used for home security alerts and custom announcements.

The Hub M3 is now available at Aqara’s Amazon brand stores throughout North America (US, Canada), Europe (France, Germany, Italy, Poland, Spain, UK) and Asia (Japan), as well as through select Aqara retailers worldwide.

For more information on the M3, please visit our website.

1. Some Aqara Home automation may require Internet and cloud service to function, for example, automations involve push notifications and location services (e.g., geofencing, local weather, sunrise/sunset).
2. Edge automation and group migration are not supported by the original Aqara Hub and Camera Hub G2H.
3. Not all Aqara Zigbee devices can be bridged to Matter.
4. Third-party Matter device support is limited to select brands and device types by the time of M3 launch.
5. The functionality of infrared AC units may vary depending on each particular Matter-enabled platform. Each M3 hub can bridge one infrared AC unit to Matter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240508489885/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

TRU Simulation’s Bell 525 Flight Simulator Receives FAA Interim Level C Qualification17.11.2025 09:00:00 CET | Press release

TRU Simulation + Training Inc., a Textron Inc. (NYSE:TXT) company, and an affiliate of Textron Aviation Inc. and Bell Textron Inc. today announced its Bell 525 Full Flight Simulator (FFS) located at the Bell Training Academy received Interim Level C qualification from the Federal Aviation Administration (FAA). Bell Textron Inc. has designed and will manufacture the Bell 525 helicopter. By achieving this milestone, pilots can earn more flight hours on the Bell 525 platform ahead of the rotorcraft’s expected FAA type certification. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117520706/en/ TRU Simulation’s Bell 525 Flight Simulator receives FAA Interim Level C qualification “The accuracy and realism of our Flight Simulation Devices play a crucial role in ensuring that pilots can effectively translate their training into real-world scenarios,” said Jerry Messaris, vice president and general manager, TRU Simulation. “This q

Polpharma Biologics Confirms U.S. Launch of Tyruko® (natalizumab), the First and Only Biosimilar for Multiple Sclerosis17.11.2025 08:52:00 CET | Press release

Polpharma Biologics, a biopharmaceutical company group focused on biosimilars development and manufacturing, today confirmed that Sandoz Tyruko® (natalizumab-sztn) is now available to patients in the United States. Tyruko® is the first and only FDA-approved biosimilar of natalizumab for the treatment of relapsing forms of multiple sclerosis (MS), and also for adult patients with moderately to severely active Crohn’s disease1. Tyruko® was developed by Polpharma Biologics and will be commercialized in the U.S. by its collaboration partner Sandoz, under an exclusive global license agreement. The launch marks a significant milestone in expanding access to high-quality, affordable treatment options for patients living with MS and Crohn’s disease in the United States. Emmanuelle Lepine, Chair of the Supervisory Board, Polpharma Biologics, commented: "The U.S. launch of Tyruko® marks a pivotal moment not only for Polpharma Biologics, but for patients across the United States. This milestone r

Lone Star Acquires Multi-Asset Real Estate Portfolio from St. James’s Place17.11.2025 08:01:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Real Estate Fund VII, L.P. has successfully completed the acquisition of a multi-asset real estate portfolio from St. James’s Place (SJP) and its Property Unit Trust and Life and Pensions Trust. SJP was advised by Invesco Real Estate, the global real estate investment manager, on the sale of the portfolio. The portfolio comprises 16 high-quality assets across the UK, including multi-let industrial (“MLI”), retail, and office properties. The largest component is the MLI portfolio, which consists of 10 separate property assets predominantly located in Greater London and South East England, and offering access to major transportation and industrial hubs — making them highly attractive for last-mile delivery and regional distribution. The office properties are all situated in London, while the retail assets consist of high-quality retail warehouses with strong tenant bases. Lone Star will implement an active asset

Bureau Veritas appoints Santiago Arias Duval as Executive Vice-President for the Americas region17.11.2025 08:00:00 CET | Press release

Bureau Veritas, a global leader in Testing, Inspection and Certification (TIC), is pleased to announce the appointment of Santiago Arias Duval, effective November 17th, 2025, as Executive Vice-President, Americas. This appointment is in line with Bureau Veritas’ new operating model effective since September 1st, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251116192035/en/ Hinda Gharbi, CEO at Bureau Veritas Bureau Veritas is evolving the structure of its executive committee to drive greater organizational alignment. This organization will empower the regions with scalable Product Lines, enabling global solutions development, and will be unlocking wider cross-selling opportunities. The Americas region is created to leverage fast developing market opportunities across countries in North, Central and South America. This is a dynamic region for all Bureau Veritas where the group intends to expand its leadership across p

Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL)17.11.2025 07:00:00 CET | Press release

Pending the European Commission decision, Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide will represent an important new therapeutic option from second line for patients with follicular lymphoma (FL) in EuropeIn Western countries, relapsed or refractory FL affects 2-4 out of every 100,000 people1The positive Committee for Medicinal Products for Human Use (CHMP) recommendation is based on data from the Phase 3 inMIND trial which showed patients with relapsed or refractory FL achieved significantly improved progression-free survival with Minjuvi in combination with rituximab and lenalidomide2 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) after at

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye